• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Immatics N.V. (Amendment)

    2/14/24 4:21:51 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    SC 13G/A 1 tm242424d18_sc13ga.htm SC 13G/A

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

     

    Immatics N.V.

    (Name of Issuer)

     

    Ordinary Shares, nominal value £0.01 per share

    (Title of Class of Securities)

     

    N44445109

     

    (CUSIP Number)

     

    December 31, 2023

     
     

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)

     

      ¨ Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No.  N44445109

     

    1   NAMES OF REPORTING PERSONS

    Baker Bros. Advisors LP  
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  (a) ¨     
     (b) ¨     
    3   SEC USE ONLY
     
    4   CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5   SOLE VOTING POWER  

    5,838,853
    6   SHARED VOTING POWER  

    -0-  
    7   SOLE DISPOSITIVE POWER  

    5,838,853
    8   SHARED DISPOSITIVE POWER  

    -0-  

    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,838,853
    10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨     
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.9% (1)
    12   TYPE OF REPORTING PERSON (See Instructions)  

    IA, PN 
               

     

      (1) Based on 84,656,114 Ordinary Shares (“Ordinary Shares”) of Immatics N.V. (the “Issuer”) outstanding as of September 30, 2023, as reported in the Issuer’s Prospectus filed with the Securities and Exchange Commission (“SEC”) on January 17, 2024.

      

     

     

    CUSIP No.  N44445109

     

    1   NAMES OF REPORTING PERSONS

    Baker Bros. Advisors (GP) LLC
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  (a) ¨     
     (b) ¨     
    3   SEC USE ONLY
     
    4   CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5   SOLE VOTING POWER  

    5,838,853
    6   SHARED VOTING POWER  

    -0-  
    7   SOLE DISPOSITIVE POWER  

    5,838,853
    8   SHARED DISPOSITIVE POWER  

    -0-  

    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,838,853
    10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨     
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.9% (1)
    12   TYPE OF REPORTING PERSON (See Instructions)  

    HC, OO
               

     

      (1) Based on 84,656,114 Ordinary Shares outstanding as of September 30, 2023, as reported in the Issuer’s Prospectus filed with the SEC on January 17, 2024.

      

     

     

    CUSIP No.  N44445109

     

    1   NAMES OF REPORTING PERSONS

    Felix J. Baker
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  (a) ¨     
     (b) ¨     
    3   SEC USE ONLY
     
    4   CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5   SOLE VOTING POWER  

    5,838,853
    6   SHARED VOTING POWER  

    -0-  
    7   SOLE DISPOSITIVE POWER  

    5,838,853
    8   SHARED DISPOSITIVE POWER  

    -0-  

    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,838,853
    10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨     
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.9% (1)
    12   TYPE OF REPORTING PERSON (See Instructions)  

    IN, HC

      

           

      (1) Based on 84,656,114 Ordinary Shares outstanding as of September 30, 2023, as reported in the Issuer’s Prospectus filed with the SEC on January 17, 2024.

     

     

     

    CUSIP No.  N44445109

     

    1   NAMES OF REPORTING PERSONS

    Julian C. Baker
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)  (a) ¨     
     (b) ¨     
    3   SEC USE ONLY
     
    4   CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
     
    5   SOLE VOTING POWER  

    5,838,853
    6   SHARED VOTING POWER  

    -0-  
    7   SOLE DISPOSITIVE POWER  

    5,838,853
    8   SHARED DISPOSITIVE POWER  

    -0-  

    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,838,853
    10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨     
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.9% (1)
    12   TYPE OF REPORTING PERSON (See Instructions)  

    IN, HC
             

      

      (1) Based on 84,656,114 Ordinary Shares outstanding as of September 30, 2023, as reported in the Issuer’s Prospectus filed with the SEC on January 17, 2024.

     

     

     

    Amendment No. 2 to Schedule 13G

     

    This Amendment No. 2 to Schedule 13G amends and restates the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a) Name of Issuer:

     

    Immatics N.V. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    Paul-Ehrlich-Straße 15

     

    72076 Tübingen, Federal Republic of Germany

     

    Item 2(a) Name of Person Filing:

     

    This Amendment No. 2 is being filed jointly by the Reporting Persons.

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

    860 Washington Street, 3rd Floor

    New York, NY 10014

    (212) 339-5690

     

    Item 2(c) Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d) Title of Class of Securities:

     

    Ordinary Shares, nominal value £0.01 per share (“Ordinary Shares”).

     

    Item 2(e) CUSIP Number:

     

    N44445109

     

     

     

     

    Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act.

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

     

    (e) ⌧ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

     

    (g) ⌧ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

     

    (j) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 2 are incorporated herein by reference.

     

    Set forth below is the aggregate number of Ordinary Shares directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons.

     

    The information set forth below is based on 84,656,114 Ordinary Shares outstanding as of September 30, 2023, as reported in the Issuer’s Prospectus filed with the Securities and Exchange Commission on January 17, 2024. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

     

     

     

    Name   Number of
    Ordinary Shares
    we own or have
    the right to acquire
    within 60 days
        Percent of Class
    Outstanding
     
    667, L.P.     458,207       0.5 %
    Baker Brothers Life Sciences, L.P.     5,380,646       6.4 %
    Total     5,838,853       6.9 %

     

    Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to have been beneficial owners of securities of the Issuer directly held by the Funds.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨. N/A

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Item 8 Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024

     

      BAKER BROS. ADVISORS LP
       
      By: Baker Bros. Advisors (GP) LLC, its general partner    
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President
         
        /s/ Julian C. Baker
        Julian C. Baker
         
        /s/ Felix J. Baker
        Felix J. Baker

     

     

    Get the next $IMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    7/15/2021$26.00 → $27.00Outperform
    SVB Leerink
    More analyst ratings

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

      Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%, mDOR not reached at mFU of 16.7 months; mPFS of 6.0 months Uveal melanoma subgroup, including tebentafusp-refractory patients shows cORR of 67%, mDOR of 11.0 months at mFU of 13.4 months; mPFS o

      5/31/25 8:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Announces First Quarter 2025 Financial Results and Business Update

      IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026IMA203 PRAME Cell Therapy: Phase 1b clinical trial ongoing with updated data in metastatic melanoma with substantially longer follow-up and additional uveal melanoma patients to be presented in an oral presentation at the 2025 ASCO Annual Meeting IMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial in solid tumors ongoing with next data update, including dose escalation and ovarian cancer data, planned in 2025IMA402 PRAME Bispecific: Phase 1a clinical trial in solid tumors ongoing with next data update at relevant dose lev

      5/13/25 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

      Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois. Updated data from the Phase 1b trial of IMA203 in patients with metastatic melanoma with substantially longer follow-up compared to the last presentation in October 2024, and including data fro

      4/23/25 10:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care